Nucleotide reverse transcriptase inhibitors

A thorough review, present status and future perspective as HIV therapeutics

Ashley D. Holec, Subhra Mandal, Pavan Kumar Prathipati, Christopher J. Destache

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.

Original languageEnglish (US)
Pages (from-to)411-421
Number of pages11
JournalCurrent HIV Research
Volume15
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Reverse Transcriptase Inhibitors
HIV-1
Nucleotides
HIV
Virus Diseases
Therapeutics
Pharmacology
United States Food and Drug Administration
Nucleosides
PubMed
Acquired Immunodeficiency Syndrome
Infection

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Virology

Cite this

Nucleotide reverse transcriptase inhibitors : A thorough review, present status and future perspective as HIV therapeutics. / Holec, Ashley D.; Mandal, Subhra; Prathipati, Pavan Kumar; Destache, Christopher J.

In: Current HIV Research, Vol. 15, No. 6, 01.12.2017, p. 411-421.

Research output: Contribution to journalReview article

@article{0aa829d9658f4653b12e9fef2021e243,
title = "Nucleotide reverse transcriptase inhibitors: A thorough review, present status and future perspective as HIV therapeutics",
abstract = "Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.",
author = "Holec, {Ashley D.} and Subhra Mandal and Prathipati, {Pavan Kumar} and Destache, {Christopher J.}",
year = "2017",
month = "12",
day = "1",
doi = "10.2174/1570162X15666171120110145",
language = "English (US)",
volume = "15",
pages = "411--421",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Nucleotide reverse transcriptase inhibitors

T2 - A thorough review, present status and future perspective as HIV therapeutics

AU - Holec, Ashley D.

AU - Mandal, Subhra

AU - Prathipati, Pavan Kumar

AU - Destache, Christopher J.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.

AB - Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.

UR - http://www.scopus.com/inward/record.url?scp=85042743713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042743713&partnerID=8YFLogxK

U2 - 10.2174/1570162X15666171120110145

DO - 10.2174/1570162X15666171120110145

M3 - Review article

VL - 15

SP - 411

EP - 421

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 6

ER -